Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMA301 in Pulmonary Arterial Hypertension
NCT04503733Phase 1Unknown
- Sponsor
- Gmax Biopharm
- Start
- Oct 2020
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of GMA301 in pulmonary arterial hypertension (PAH) (5 arms), sponsored by Gmax Biopharm. Primary endpoint: Treatment-emergent Adverse Events at 22 weeks. Status: unknown.
02
Drugs
GMA301
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04503733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503733.